RT Journal Article
SR Electronic
T1 Trans-ancestry genome-wide analysis of atrial fibrillation provides new insights into disease biology and enables polygenic prediction of cardioembolic risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.06.21263189
DO 10.1101/2021.09.06.21263189
A1 Miyazawa, Kazuo
A1 Ito, Kaoru
A1 Zou, Zhaonan
A1 Matsunaga, Hiroshi
A1 Koyama, Satoshi
A1 Ieki, Hirotaka
A1 Nomura, Seitaro
A1 Akiyama, Masato
A1 Kurosawa, Ryo
A1 Yoshida, Hiroki
A1 Ozaki, Kouichi
A1 Onouchi, Yoshihiro
A1 ,
A1 Takahashi, Atsushi
A1 Matsuda, Koichi
A1 Murakami, Yoshinori
A1 Aburatani, Hiroyuki
A1 Kubo, Michiaki
A1 Momozawa, Yukihide
A1 Terao, Chikashi
A1 Oki, Shinya
A1 Akazawa, Hiroshi
A1 Kamatani, Yoichiro
A1 Komuro, Issei
YR 2021
UL http://medrxiv.org/content/early/2021/09/12/2021.09.06.21263189.abstract
AB To understand the genetic underpinnings of atrial fibrillation (AF) in the Japanese population, we performed a large-scale genome-wide association study comprising 9,826 cases of AF among 150,272 individuals and identified five new susceptibility loci, including East Asian-specific rare variants. A trans-ancestry meta-analysis of >1 million individuals, including 77,690 cases, identified 35 novel loci. Leveraging gene expression and epigenomic datasets to prioritize putative causal genes and their transcription factors revealed the involvement of IL6R gene and transcription factor ERG besides the known ones. Further, we constructed a polygenic risk score (PRS) for AF, using the trans-ancestry meta-analysis. PRS was associated with an increased risk of long-term cardiovascular and stroke mortality, and segregated individuals with cardioembolic stroke in undiagnosed AF patients. Our results provide novel biological and clinical insights into AF genetics and suggest their potential for clinical applications.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementThis research was funded by the GRIFIN project of the Japan Agency for Medical Research and Development (AMED) (nos. JP20km0405209 and JP20ek0109487 to K. Miyazawa, K. I, S. K., S. N., H. Akazawa, and I. K.), MSD Life Science Foundation (to K. Miyazawa), the Japan Society for the Promotion of Science (to K. Miyazawa, K. I. and H. I.), and Sakakibara Memorial Research Grant from The Japan Research Promotion Society for Cardiovascular Diseases (to H. M.). BBJ was supported by the Tailor-Made Medical Treatment Program of the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) and AMED under grant numbers JP17km0305002 and JP17km0305001.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples were at least 18 years old. Informed consent was obtained from all participants, and our study was approved by the relevant ethical committees at each facility.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics of Japanese GWAS and polygenic risk scores derived in this study will be publicly available at the National Bioscience Database Center (https://humandbs.biosciencedbc.jp/). https://humandbs.biosciencedbc.jp/